Cantor Fitzgerald Forecasts bluebird bio FY2025 Earnings

bluebird bio, Inc. (NASDAQ:BLUE) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of bluebird bio in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the biotechnology company will post earnings per share of ($23.60) for the year. The consensus estimate for bluebird bio’s current full-year earnings is ($27.17) per share.

Several other research firms have also issued reports on BLUE. Bank of America lowered shares of bluebird bio from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $60.00 to $10.00 in a report on Friday, November 15th. Wells Fargo & Company lowered their target price on shares of bluebird bio from $60.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Wednesday, September 25th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $80.00 price target on shares of bluebird bio in a research note on Friday, November 15th. Barclays boosted their price objective on bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, December 31st. Finally, JPMorgan Chase & Co. cut bluebird bio from a “neutral” rating to an “underweight” rating in a research report on Friday, November 15th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $49.14.

bluebird bio Stock Performance

Shares of BLUE opened at $8.14 on Wednesday. bluebird bio has a 52 week low of $5.80 and a 52 week high of $38.40. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The stock has a market cap of $79.14 million, a price-to-earnings ratio of -0.22 and a beta of 0.68. The business has a 50-day simple moving average of $8.12 and a two-hundred day simple moving average of $12.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC boosted its holdings in shares of bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 184,605 shares during the period. Geode Capital Management LLC boosted its stake in bluebird bio by 3.7% during the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock worth $2,433,000 after buying an additional 166,771 shares during the period. State Street Corp increased its position in bluebird bio by 1.1% during the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after acquiring an additional 43,382 shares during the last quarter. Verition Fund Management LLC purchased a new stake in shares of bluebird bio in the third quarter valued at $42,000. Finally, Captrust Financial Advisors lifted its holdings in shares of bluebird bio by 48.2% in the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 77,293 shares during the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.